Skip to content

Dr. Mark Sutherland

Information about Dr. Mark Sutherland at the University of Bradford.

Some details are missing for this profile, including contact information. If this is your profile, please review guidance on how to report this issue.

Photo of Dr. Mark Sutherland


Dr Mark Sutherland is a Lecturer in Biochemistry in the School of Chemistry and Biosciences, University of Bradford. After completing his MSc in Microbiology at the University of Stellenbosch, South Africa he worked for a few years as a school teacher and University Lecturer. He was offered a PhD at the Charite – Campus Benjamin Franklin, Berlin, Germany where he received his doctorate in Medical Biochemistry. He then worked for a number of years as a PDRA in Berlin in the field of immunotoxins. This work resulted in a number of publications, review articles and book chapters. In 2005 he moved to the Institute of Cancer Therapeutics at the University of Bradford. He carried out research for a number of projects within the Institute to generate proof-of-concept data for grant and patent applications. He also taught laboratory skills to MSc and PhD students, and lectured undergraduate and MSc students. His research was in the field of integrins as a target for new anti-cancer drugs in prostate cancer and melanoma, as well as the role of sialyltransferases in neuroblastoma. The research involves a wide range of methodologies including generating lentivirus knockout models (shRNA), development of an ELISA for biomarker analysis, protein expression/purification using GST-tagged protein in E.coli and luciferase reporter assays. This work has led to numerous publications, and successful grant applications. Dr Sutherland has vast experience in an array of Molecular Biology techniques including gene cloning, transformation/transfection, Western blotting, PCR and qPCR; as well as managing the Molecular Biology Laboratory. He started his current role as Lecturer in January 2019.

Professional activities

Information about education, employment and areas of particular interest for Dr. Mark Sutherland is as follows:


  • University of Bradford - Senior Experimental Officer in the year 2005 (specified as 01/11/2005)
  • Cape Education Departmant - Science and Mathematics teacher in the year 1994 (specified as 01/01/1994)
  • University of Fort Hare, South Africa - Lecturer in Biochemistry and Microbiology in the year 1995 (specified as 01/01/1995)
  • University of Stellenbosch, South Africa - Research Assistant in the year 1993 (specified as 01/01/1993)
  • Charite - Klinikum Benjamin Franklin - PDRA in the year 2000 (specified as 01/11/2000)


  • University of Cape Town, South Africa - BSc
  • University of Stellenbosch, South Africa - BSc (Hon)
  • University of Stellenbosch, South Africa - MSc
  • Charite Campus Benjamin Franklin - PhD (rer med)


There are 15 publications involving or that are attributed to Dr. Mark Sutherland. They are listed as:

  • book chapter (1)
  • peer reviewed journal (11)
  • reviews (3)

Book Chapter

Dr. Mark Sutherland has 1 publication(s) listed under book chapter.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Preclinical Studies of Saponins for Tumor Therapy 2015 Recent Advances in Medicinal Chemistry Recent Advances in Medicinal Chemistry 1 272 - 302 Bachran C.;Bachran S.;Sutherland M.;Bachran D.;Fuchs H. 9780128039618 10.1016/B978-0-12-803961-8.50009-9

Peer Reviewed Journal

Dr. Mark Sutherland has 11 publication(s) listed under peer reviewed journal.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity 2011 Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H.
Quantification of diphtheria toxin-mediated ADP-ribosylation in a solid-phase assay 2007 Clinical Chemistry 53 1676 - 1683 Bachran C.;Sutherland M.;Bachran D.;Fuchs H. 0009-9147 10.1373/clinchem.2007.085365
The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure 2006 Experimental Biology and Medicine 231 412 - 420 Bachran C.;Sutherland M.;Heisler I.;Hebestreit P.;Melzig M.;Fuchs H. 1535-3702 10.1177/153537020623100407
A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin 2011 Life Sciences 88 226 - 232 Bachran C.;Schneider S.;Riese S.;Bachran D.;Urban R.;Schellmann N.;Zahn C.;Sutherland M.;Fuchs H. 0024-3205 10.1016/j.lfs.2010.11.012
Improved preparation and detection of cytochrome P450 isoforms using MS methods 2010 Proteomics 10 327 - 331 Sutton C.;Sutherland M.;Shnyder S.;Patterson L. 1615-9853 10.1002/pmic.200900489
Exploring and Exploiting Acceptor Preferences of the Human Polysialyltransferases as a Basis for an Inhibitor Screen 2017 ChemBioChem 18 1332 - 1337 Ehrit, J.; Keys, T.G.; Sutherland, Mark H.; Wolf, S.; Meier, C.; Falconer, R.A.; Gerardy-Schahn, R. 10.1002/cbic.201700157
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity 2013 Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue 2015 MedChemComm 6 187 - 191 Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus
An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity 2016 ANALYST (PRINT) 141 5849 - 5856 Elkashef, Sara M.; Sutherland, Mark H.; Patterson, Laurence H.; Loadman, Paul M.; Falconer, Robert A. 10.1039/c6an01073c
Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration 2013 PLoS ONE 8 e73366 Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. 10.1371/journal.pone.0073366
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder 2013 Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H.


Dr. Mark Sutherland has 3 publication(s) listed under reviews.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Saponins in tumor therapy 2008 Mini-Reviews in Medicinal Chemistry 8 575 - 584 Bachran C.;Bachran S.;Sutherland M.;Bachran D.;Fuchs H. 1389-5575 10.2174/138955708784534445
Saponins as tool for improved targeted tumor therapies 2009 Current Drug Targets 10 140 - 151 Fuchs H.;Bachran D.;Panjideh H.;Schellmann N.;Weng A.;Melzig M.;Sutherland M.;Bachran C. 1389-4501 10.2174/138945009787354584
RGD-binding integrins in prostate cancer: Expression patterns and therapeutic prospects against bone metastasis 2012 Cancers 4 1106 - 1145 Sutherland M.;Gordon A.;Shnyder S.;Patterson L.;Sheldrake H. 2072-6694 10.3390/cancers4041106